Mounjaro weight loss injections before and after: what actually changes, and how fast

What did the SURMOUNT-1 trial actually measure before and after 72 weeks?

SURMOUNT-1 recruited adults with a BMI of 30 or above (or 27-plus with at least one weight-related condition) who did not have type 2 diabetes. At the 15 mg dose, participants lost an average of around 20–21% of their starting body weight by week 72. At 10 mg the average was roughly 19%, and at 5 mg around 16%. Every group outperformed placebo by a wide margin.

Beyond the scales, the trial documented reductions in waist circumference of around 14–16 cm at the highest dose. Blood pressure, fasting insulin and triglycerides also improved. These secondary outcomes matter because the NHS tirzepatide medicine page explains that Mounjaro is licensed not simply for weight loss in isolation but as part of managing weight-related health as a whole.

What the numbers cannot capture is the pace. Weight loss in the trial was not linear. The first four weeks, at the 2.5 mg starter dose, tend to produce modest change, that dose exists mainly to let the body adjust rather than to drive significant loss. The steeper drops came as doses increased through 5 mg, 7.5 mg, 10 mg and beyond. Patience with the early weeks is genuinely important.

How do people's before-and-after experiences compare to the trial results?

Clinical trial populations are carefully selected, which means average trial figures are a ceiling as much as a benchmark. Adherence, diet quality, activity levels and individual metabolism all influence outcomes. People who pair Mounjaro injections with meaningful changes to eating patterns and regular movement tend to see results closer to the trial averages; those who make fewer lifestyle adjustments typically see more modest changes.

The appetite suppression that tirzepatide produces (through its dual action on GIP and GLP-1 receptors) means many people find their relationship with food shifts noticeably within the first few weeks. Portion sizes fall. Snacking between meals becomes less automatic. These behavioural changes compound over months, which is why the before-and-after gap often widens most visibly between months three and nine of treatment.

If you want a fuller sense of how Mounjaro's weight loss injections work across the treatment period, that page covers the mechanism and the dose schedule in more detail. Worth reading before starting, or before increasing a dose.

What side effects are part of the before-and-after picture?

Any honest account of before and after has to include what the transition period feels like. Gastrointestinal effects are the most commonly reported: nausea, loose stools, constipation, indigestion and burping. They tend to be most noticeable in the first week or two after a new or increased dose, then settle for most people. Fatigue and mild headaches also appear in the early weeks for some.

On 29 January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines flagging acute pancreatitis as an infrequent but serious risk. Severe, persistent stomach pain (especially if it radiates to the back) needs urgent medical attention, not a wait-and-see approach.

Practically, many people find it helps to keep the pen in the fridge door rather than tucked at the back, so injection day is a visible weekly prompt rather than something that gets forgotten. Injection sites should be rotated between the abdomen, thigh and upper arm; your patient information leaflet covers this in full. If you are curious about what to expect from the Mounjaro pen before and after you begin using it, that page walks through the practical and physical changes in detail. If you have questions about the injection technique itself, our FAQs address the most common ones.

Who reaches the kind of before-and-after outcomes the trials showed?

The licensed eligibility criteria are a starting point. Adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes, may qualify for treatment. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE's appraisal of tirzepatide, TA1026, sets out the criteria for NHS access, which are stricter than the licensed thresholds.

Private treatment through a regulated pharmacy is available for people who meet the licensed criteria but do not yet qualify for NHS provision, or who prefer not to wait. There is a meaningful cost consideration there, and a clear overview of Mounjaro pricing in the UK is worth reading before committing. The important thing is that any route (NHS or private) requires clinical assessment by a prescriber. BMI alone does not determine suitability; your full health history does.

If you are considering weight loss injections like Mounjaro to understand how they compare and whether one suits your situation, a free consultation is the right next step. A prescriber reviews your answers the same day, a real clinician, reading your case, not automated software. It is also worth knowing that if you would prefer face-to-face support, you can search for Mounjaro weight loss injections near you to find regulated providers in your area. Our guide to weight loss injections using tirzepatide is also a useful starting point if you want to understand the treatment before speaking to a prescriber. Check your eligibility here.